Jun Zhang
YOU?
Author Swipe
View article: Abnormalities and Plasticity of White Matter Functional Networks in Opioid Use Disorder: A BOLD fMRI Study
Abnormalities and Plasticity of White Matter Functional Networks in Opioid Use Disorder: A BOLD fMRI Study Open
This study investigated the organization and neural activity of white matter functional networks (WMFNs) in individuals with opioid use disorder (OUD) before and after detoxification, compared with healthy controls (HC). Using a data-drive…
View article: Conditional survival prediction in elderly patients with hormone receptor positive locally advanced breast cancer using a competing risks model
Conditional survival prediction in elderly patients with hormone receptor positive locally advanced breast cancer using a competing risks model Open
This study investigated the CS patterns in elderly patients with HR-positive LABC and develop personalized CS prediction models. These models may assist in patient counseling, guide clinical decision-making, and support healthcare resource…
View article: A novel compound heterozygous variation of CRPPA in a fetus with Walker-Warburg Syndrome: A Case Report and Literature Review
A novel compound heterozygous variation of CRPPA in a fetus with Walker-Warburg Syndrome: A Case Report and Literature Review Open
View article: Patient preferences for EGFR mutation-targeted therapies in non-small cell lung cancer, with a focus on Exon 20 insertions
Patient preferences for EGFR mutation-targeted therapies in non-small cell lung cancer, with a focus on Exon 20 insertions Open
View article: Stage-specific efficacy of pharmacological interventions on gait impairments in Parkinson’s disease
Stage-specific efficacy of pharmacological interventions on gait impairments in Parkinson’s disease Open
Objective This study aims to clarify the variations and the therapeutic effects of medicine on gait by analyzing the gait characteristics before and after medication in various stages of Parkinson’s disease (PD). Methods This prospective s…
View article: Estrogen improves sevoflurane-induced cognitive dysfunction by regulating synaptic zinc homeostasis
Estrogen improves sevoflurane-induced cognitive dysfunction by regulating synaptic zinc homeostasis Open
Background Sevoflurane is known to induce cognitive dysfunction, but the underlying mechanisms remain unclear. Recent evidence suggests that disruptions in synaptic zinc homeostasis may contribute to neurotoxicity and cognitive impairment.…
View article: Table 1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Table 1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Participant demographics and baseline characteristics.
View article: Supplemental Fig S9 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Fig S9 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Fig S9. Plasma Conc. vs Time Profiles of Total ADC in C1 Following Zilovertamab Vedotin IV Twice Every 3 Wks
View article: Supplemental Table S2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Table S2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Table S2. Representativeness of the Study Population
View article: Table 2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Table 2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Summary of efficacy resultsa.
View article: Supplemental Table S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Table S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Table S6. Geometric Mean Plasma PK Parameter Values in C1 Following Zilovertamab Vedotin IV Twice Every 3 Wks
View article: Supplemental Table S3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Table S3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Table S3. Study Drug Exposure and Follow-Up Duration
View article: Supplemental Fig S10 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Fig S10 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Fig S10. Plasma Conc. vs Time Profiles of MMAE in C1 Following Zilovertamab Vedotin IV Twice Every 3 Wks
View article: Supplemental Fig S8 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Fig S8 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Fig S8. Plasma Conc. vs Time Profiles of Total AB in C1 Following Zilovertamab Vedotin IV Twice Every 3 Wks
View article: Supplemental Table S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Table S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Table S7. ROR1 and Ki-67 IHC Expression for Participants With Short and Longer Durations of Treatment
View article: Supplemental Fig S1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Fig S1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Fig S1. Study Design
View article: Supplemental Table S4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Table S4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Table S4. Efficacy Results per RECIST Version 1.1 by Investigator Assessment
View article: Supplemental Fig S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Fig S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Fig S6. Plasma Conc. vs Time Profiles of Total ADC in C1 Following Zilovertamab Vedotin IV Once Every 3 Wks
View article: Supplemental Fig S3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Fig S3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Fig S3. Swimlane Plots for Response Events and Disposition During Study Treatment per BICR
View article: Supplemental Fig S4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Fig S4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Fig S4. Swimlane Plots for Response Events and Disposition During Study Treatment by Investigator
View article: Supplemental Fig S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Fig S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Fig S5. Plasma Conc. vs Time Profiles of Total AB in C1 Following Zilovertamab Vedotin IV Once Every 3 Wks
View article: Supplemental Table S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Table S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Table S5. Geometric Mean Plasma PK Parameter Values in C1 Following Zilovertamab Vedotin IV Once Every 3 Wks
View article: Table 3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Table 3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Summary of AEs.
View article: Table 4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Table 4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Most commona treatment-related AEs.
View article: Supplemental Fig S2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Fig S2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Fig S2. Participant Disposition
View article: Supplemental Table S1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Table S1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Table S1. Dose Reduction Levels for the Twice Every 3 Weeks Dosing Schedule
View article: Supplemental Fig S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Supplemental Fig S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Supplemental Fig S7. Plasma Conc. vs Time Profiles of MMAE in C1 Following Zilovertamab Vedotin IV Once Every 3 Wks
View article: Data from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Data from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors Open
Purpose:Zilovertamab vedotin, an antibody–drug conjugate targeting receptor tyrosine kinase–like orphan receptor 1 (ROR1), had manageable safety and promising antitumor activity in participants with relapsed or refractory non–Hodgkin lymph…
View article: Impact of subaxial cervical spine surgeries on patients' head-cervical spine mobility: measurement with CROM device
Impact of subaxial cervical spine surgeries on patients' head-cervical spine mobility: measurement with CROM device Open
Objective: To assess and compare the impact of two different subaxial cervical spine surgeries (four groups) on patients’ postoperative head-cervical spine mobility (HCSM) function. Method: Using the CROM device, postoperative six-directio…
View article: Estrogen Alleviates Sevoflurane‐Induced Neurotoxicity by Inhibiting ERα‐Tau Binding
Estrogen Alleviates Sevoflurane‐Induced Neurotoxicity by Inhibiting ERα‐Tau Binding Open
Sevoflurane‐induced neurotoxicity is age‐dependent, but the role of sex differences is unclear. While testosterone has protective effects, the impact of estrogen remains unknown. This study investigates the effects of sevoflurane on neurot…